Login to Your Account



Pacira Prepares IPO, Reports Phase III Data for Exparel

By Catherine Shaffer


Tuesday, January 18, 2011
Pacira Pharmaceuticals Inc. has big plans for 2011. The Parsippany, N.J.-based company expects to make an initial public offering with expected net proceeds of up to $65.9 million to get its lead analgesic candidate Exparel (bupivacaine) off the ground.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription